Fatigue Symptom Distress and Its Relationship with Quality Of Life in Adult Stem Cell Transplant Survivors by Abduljawad, Suzan Fouad, R.N., B.S.N.
University of South Florida 
Scholar Commons 
Graduate Theses and Dissertations Graduate School 
11-16-2009 
Fatigue Symptom Distress and Its Relationship with Quality Of 
Life in Adult Stem Cell Transplant Survivors 
Suzan Fouad Abduljawad R.N., B.S.N. 
University of South Florida 
Follow this and additional works at: https://scholarcommons.usf.edu/etd 
 Part of the American Studies Commons 
Scholar Commons Citation 
Abduljawad, Suzan Fouad R.N., B.S.N., "Fatigue Symptom Distress and Its Relationship with Quality Of Life 
in Adult Stem Cell Transplant Survivors" (2009). Graduate Theses and Dissertations. 
https://scholarcommons.usf.edu/etd/1819 
This Thesis is brought to you for free and open access by the Graduate School at Scholar Commons. It has been 
accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. 
For more information, please contact scholarcommons@usf.edu. 
   
 
 
Fatigue Symptom Distress and Its Relationship with Quality Of Life in Adult Stem 
Cell Transplant Survivors  
 
 
by 
 
 
 
Suzan Fouad Abduljawad, R.N., B.S.N. 
 
 
 
 
 
A thesis submitted in partial fulfilment 
of the requirements for the degree of 
Master of Science 
College of Nursing 
University of South Florida 
 
 
 
 
 
Major Professor: Susan C. McMillan, Ph.D., A.R.N.P. 
Cindy S. Tofthagen, Ph.D., A.R.N.P. 
Brandy L. Lehman, Ph.D., R.N. 
 
 
 
 
Date of Approval: 
November 16, 2009  
 
 
 
Keywords: cancer, adults, persistent fatigue, survivors, bone marrow transplant. 
 
© Copyright 2009 , Suzan Fouad Abduljawad 
 
 
 
   
 
 
 
DEDICATION 
This thesis is dedicated to my outstanding mother, Khadija Elmoujarrad. Her 
devotion, hard work, and thirst for knowledge inspired my motivation to pursue my 
Master of Science degree, and the completion of this thesis. Thank you mother, your 
endless love, support, prayers and encouragement put me on the road to success. To 
my deceased father, Fouad Abduljawad, who had always encouraged me to learn and 
dream big, I wish you were here to witness the success of your daughter getting the 
honor of being the first female to attain the Master’s degree in the family. I would like 
to also dedicate this thesis to my husband, Abdullah Wolkens, for his love, support, 
and willingness to put my needs before his own. Thank you for believing in me. And 
last but not least, I dedicate this to my beloved family. Grandmother Aicha El-Eidi 
and Grandfather Jeloul Elmoujarrad, thank you for your unconditional love and your 
continuous prayers; my brother Feras, who inspired me with his enthusiasm for higher 
education and greater knowledge; my brother Fahad and sister Sundus, I appreciate 
your love and encouragement, I hope you may find this thesis a source for your own 
inspiration. I am blessed to have each and every one of you in my life. 
   
 
 
 
ACKNOWLEDGMENTS 
 All Praises to Allah, Lord of the Universe, thank you for the strength that 
keeps me standing and for the faith that brought light to my path and guided me. I am 
forever in debt for your blessings with the people who have given their heart 
whelming full support and encouragement in preparation of this thesis. 
 I would like to thank Dr. Susan McMillan, for the direction throughout this 
project. I am short of words to express my gratitude for your guidance, your 
encouragement, your tireless support, and above all because you had faith in my 
success. I would also like to acknowledge my thesis committee members, Dr. Cindy 
Tofthagen and Dr. Brandy Lehman for their time and contribution. I am extremely 
grateful to Dr. Dee Dee Boyington for her invaluable help and support of my research 
study. When new obstacles presented at every turn in the road to approval I was 
blessed by having you help push it through. I am thankful to Doreen Appunn, MCC 
Division of Research Compliance, for her great help and guidance. Many thanks to 
Trudy Wittenberg USF unit research administrator, for helping me through my IRB 
application. And finally, I am grateful to all the men and women who took part in my 
study for seeing its value and taking the time to participate.
  i 
 
 
 
 
Table of Contents 
List of Tables ............................................................................................................... iii 
Abstract ........................................................................................................................ iv 
 
Chapter I Introduction ....................................................................................................1 
 Statement of Problem .........................................................................................1
 Research Questions ............................................................................................2 
 Definition of Terms............................................................................................2 
 Significance to Nursing......................................................................................3 
 
Chapter II Review of Literature .....................................................................................5 
 Fatigue................................................................................................................5 
Quality of Life..................................................................................................12 
Summary ..........................................................................................................15 
 
Chapter III Methods .....................................................................................................17 
Setting and Sample ..........................................................................................17 
Instrumentation ................................................................................................18 
Cancer Related Fatigue Distress Scale (CRFDS) ................................18 
Validity and Reliability ............................................................19 
Functional Assessment of Cancer Therapy-Bone Marrow  
   Transplant (FACT-BMT)...............................................................19 
Validity and Reliability ............................................................20 
Demographic data Form ......................................................................20 
Procedures ........................................................................................................21 
Approvals .............................................................................................21 
Data Collection ....................................................................................21 
Data Analysis .......................................................................................22 
 
Chapter IV Results, Discussion and Conclusions ........................................................24 
 Results ..............................................................................................................24 
 Sample..................................................................................................24 
 Fatigue Intensity and Symptom Distress .............................................26 
  Relationship between Fatigue Symptom Distress and QOL................28 
  Relationship between Fatigue Symptom Distress and Time from  
   Transplant ......................................................................................28 
  Relationship between QOL and Time from Transplant .......................28 
 Discussion ........................................................................................................29 
  Sample..................................................................................................29 
  Fatigue Symptom Distress and Quality of Life ...................................30 
  Relationship between Fatigue Symptom Distress and QOL................31 
  ii 
 
 
 Relationship between Time from Transplant, Fatigue Symptom  
  Distress and QOL ...........................................................................31 
 Conclusions ......................................................................................................32 
  Implications for Nursing ......................................................................32 
  Implications for Research ....................................................................33 
 
References ....................................................................................................................34 
 
Appendices ...................................................................................................................36 
 Appendix A: Cancer Related Fatigue Distress Scale (CRFDS) ......................37 
Appendix B: Functional Assessment of Cancer Therapy–Bone Marrow  
 Transplant ..................................................................................................41 
Appendix C: Demographic Data/Health History Information Form ...............44 
Appendix D: Informed Consent .......................................................................45 
Appendix E: Moffitt Cancer Center Scientific Review Committee approval .50 
 Appendix F: Institutional Review Board Approval .........................................52 
  iii 
 
 
 
 
List of Tables 
 
Table 1 Demographics and Clinical Characteristics of Patients .......................25 
Table 2 Diagnoses and Type of Transplant ......................................................26 
Table 3  Fatigue Intensity Score ........................................................................27 
Table 4  Total Scores of CRFDS and FACT-BMT ...........................................28 
Table 5 Pearson Correlation Coefficients between Fatigue Symptom  
 Distress, Quality of Life, and Time from Transplant ...........................29 
  iv 
 
 
 
 
Fatigue Symptom Distress and Its Relationship with Quality Of Life in Adult Stem 
Cell Transplant Survivors  
 
Suzan Fouad Abduljawad 
ABSTRACT 
 Fatigue is a common problem among cancer patients, especially those who 
have received chemotherapy and radiation therapy. Stem cell transplant (SCT) 
patients are at a particular risk of persistent fatigue as they receive more aggressive 
therapies. This study examined the prevalence of fatigue after completion of SCT. 
Further, the level of fatigue symptom distress and its relationship with quality of life 
(QOL) among long term SCT survivors was examined. 
 The study involved thirty-three patients, 21 males and 12 females, treated with 
autologous or allogeneic SCT in a comprehensive cancer center in Southwest Florida. 
Participants’ ages ranged from 36 to 70 years, with a mean age of 53 years. All 
subjects completed the Cancer Related Fatigue Distress Scale and the Functional 
Assessment of Cancer Therapy-Bone Marrow Transplant questionnaires. All the 
patients had to be at least six months from transplant.  
 The results of this study showed that fatigue is quite prevalent among SCT 
survivors. Ninety-three percent of the patients reported some degree of fatigue, and 
15% experienced severe fatigue. Patients who received autologous transplant (24%) 
reported less fatigue symptom distress (mean= 48, SD= 36.62) compared to the 
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allogeneic transplant group (mean= 66.2, SD= 54.49). A strong negative relationship 
was found between fatigue symptom distress and QOL (r = 0.85, p < 0.0001) 
suggesting that patients with the greatest fatigue distress report the worst QOL. The 
time from transplant factor was significantly positively associated with fatigue 
symptom distress (r= 0.46, p= 0.007) indicating greater distress with the passage of 
time. A moderate negative relationship was also found between time from transplant 
and QOL (r= -0.34, p= 0.052) suggesting that QOL was less in some patients as time 
passed; however this was a weak relationship that did not achieve statistical 
significance. 
 Although the sample size was small, this study was able to provide a 
confirmation that fatigue symptom distress and QOL are related to one another. 
Understanding the relationship between fatigue symptom distress and QOL should 
encourage interdisciplinary collaboration in planning proper interventions to minimize 
fatigue. This would improve the outcomes of SCT long term survivors, and would 
positively impact their overall QOL.
 
 
 
 
 
Chapter I 
Introduction 
Fatigue is a common symptom of cancer that has been demonstrated by 
research to be one of the most distressing symptoms associated with cancer and all 
cancer treatment modalities including chemotherapy, surgery, biotherapy, radiation 
therapy, and bone marrow transplantation. It is reported that 70 to 100% of patients 
who are undergoing cancer treatment suffer from fatigue at some or all stages of their 
illness (Flude, Groll, Tranmen, & Woodend, 2007).  This distressing symptom can 
interfere with many aspects of QOL, including physical, psychosocial and spiritual 
well being. Cancer patients undergoing stem cell transplant (SCT) are subject to 
receiving high doses of chemotherapy and radiation therapy in bone marrow 
conditioning regimens prior to transplant. The side effects from this multi-treatment 
approach often precipitate heightened levels of fatigue (Gielissen et al., 2007). 
Persistent burden on the physical and psychological status contributes to decreased 
levels of activity, cognitive ability and the resultant poor sense of well being (Harder 
et al., 2002). Certainly symptom management is a priority for those who strive to 
improve patients’ outcomes. With growing evidence that SCT patients suffer from 
persistent fatigue, it should be equally important for the clinicians and researchers to 
understand this phenomenon and examine its relationship to QOL of SCT survivors. 
Statement of the Problem 
Fatigue is a common side effect that can be expected in the immediate 
recovery period of SCT (El-Banna et al., 2004). When the transplantation journey 
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concludes, the patients hope to regain their pre-diagnosis health status, functional 
ability, and their psychological, social and spiritual well being, to again lead their 
lives somewhat normally. Unfortunately, some patients experience a lingering fatigue 
that begins with their diagnosis of cancer, and continues in some cases for years after 
the completion of successful therapy. However, the factors contributing to the 
persistence of this problem and its impact on overall survival remains poorly 
understood. Thus, this study sought to describe the phenomenon of persistent fatigue, 
and how fatigue symptom distress is related to quality of life in long term SCT 
survivors. 
Research Questions 
The following questions guided the study: 
1. What is the prevalence of fatigue and the level of fatigue symptom distress 
reported by cancer patients at least six months past completing SCT?  
2. What do patients report their QOL to be at least six months after SCT? 
3. Is there a significant relationship between fatigue symptom distress and QOL of 
cancer patients at least six months after SCT?  
4. Is there a significant relationship between fatigue and time from transplant? 
5. Is there a significant relationship between QOL and time from transplant? 
Definition of Terms 
For the purpose of this paper the following definitions are used. 
Fatigue: An unusual, sustained, subjective sense of tiredness, malaise or lack 
of energy, related to cancer or cancer treatment that interferes with usual functioning 
(The National Comprehensive Cancer Network [NCCN], 2008).  
Fatigue Symptom Distress: It is the distress and suffering that accompanies the 
experience of the fatigue symptom (Holley, 2000). 
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Quality of life: Is a subjective multidimensional construct that represents 
aspects of the individual’s satisfaction with well being. It is defined as the difference 
or gap between the current hopes and expectation of the individual and that 
individual's present experiences (Frick, Borasio, Zehentner, Fischer, & Bumeder 
2004).  
Stem cell transplantation: Is a procedure used to restore the stem cells when the 
bone marrow has been destroyed by disease, radiation or chemotherapy. Depending 
on the source of the stem cells, this procedure may be called a bone marrow transplant 
(BMT), a peripheral blood stem cell transplant (PBSCT), or a cord blood transplant 
(American Cancer Society, 2009).  
Autologous stem cell transplantation (ASCT): A procedure in which blood-
forming stem cells are harvested from the blood stream, stored, and later transfused 
back to the same person (American Cancer Society, 2009).  
Allogeneic stem cell transplantation (aSCT): A procedure in which a person 
receives blood-forming stem cells from a genetically similar, but not identical, donor. 
This is often a sister or brother, but could be an unrelated donor (American Cancer 
Society, 2009).  
Significance to Nursing 
Describing the post transplant fatigue phenomenon is of particular significance 
in improving SCT patients’ outcomes. In order to be able to design and achieve 
optimal management of this distressing symptom, healthcare professionals need to 
understand the magnitude of the problem. The knowledge of prevalence and severity 
of fatigue reported by cancer patients after SCT, coupled with examining the quality 
of life in relation to reports of the fatigue distress should help focus post transplant 
nursing care. The information obtained from this study can assist nursing clinicians 
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and researchers, who strive to improve patients’ outcomes, in recognizing the impact 
of fatigue on quality of life. This will further refine the clinicians’ timing of 
supportive interventions and the content of education they provide to patients.  
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Chapter II 
Review of Literature 
This chapter presents the review of literature that is associated with fatigue and 
the quality of life following SCT treatment in patients with hematologic malignancies. 
First studies of fatigue are reviewed. This is followed by studies of quality of life, and 
finally the literature is summarized. 
Fatigue 
In the past two decades, stem cell transplantation, following a conditioning 
regimen of intensive high dose chemotherapy with or without total body irradiation, 
has been used increasingly as means for a potential cure of many hematologic 
diseases and malignancies (Hjermstad et al., 2004). This approach to treatment, 
despite its effectiveness in decreasing mortality, is often complicated with unpleasant 
symptoms and side effects that can be extremely daunting and at times even life 
threatening. 
The incidence and intensity of cancer related fatigue in BMT recipients varies 
over the course of treatment and recovery. In a longitudinal study, El-Banna et al. 
(2004) described the temporal patterns of depression and the four dimensions of 
cancer related fatigue including: behavioral, sensory, cognitive and affective meaning. 
Twenty-seven adult patients with lymphoma undergoing autologous stem cell 
transplantation (ASCT) were included in this study. Fatigue was measured over 
multiple time points; at baseline before chemotherapy initiation, on chemotherapy 
day, and on recovery at days 2, 7, and 14. The authors used the revised Piper Fatigue 
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Scale (PFS), a multidimensional self-report fatigue instrument, on which high scores 
indicate higher levels of perceived fatigue. El-Banna et al. (2004) found variations 
over the two-week period following ASCT. The patients reported significant increase 
of PFS scores from baseline to day seven for total fatigue and all dimensions of 
fatigue except the cognitive or mood subscale. The pattern showed a decline after day 
14 of transplantation. To measure depression, The Center for Epidemiologic Studies–
Depression (CES-D) Scale was used. Total scores on the CES-D scale range from 
zero (no depression) to 60 (severe depression). A score of 16 or more on the CES-D 
scale indicates depressive symptoms. The authors also found depression presenting a 
similar pattern of sharp increase on day seven and a gradual decline afterwards with a 
high positive correlation between affective fatigue and depression (p < 0.01). The 
findings of this study highlight the importance of continuity of care, measuring 
fatigue with concurrent assessment for depression, and paying close attention to the 
immediate recovery period where the peak of these symptoms seems to occur. 
From the NCCN definition of fatigue one can find the concept of fatigue 
rendered with much influence on physical activity and functional ability. In a 
prospective study, Hacker et al. (2006) sought to examine the feasibility of obtaining 
real-time fatigue and physical activity data, to describe the patterns of fatigue, 
physical activity, health status, and quality of life before and after hematopoietic stem 
cell transplantation (HSCT). Twenty adult patients undergoing autologous or 
allogeneic HSCT participated in the study. To assess fatigue, two different measures 
were used, the fatigue subscale of the European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire-core 30 (EORTC QLQ-C30) and 
the Actiwatch (a wrist actigraph with a subjective event marker which was used as a 
self report scale to measure real-time fatigue intensity). The Actiwatch was also used 
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to measure physical activity of the patients as the device consisted of an 
accelerometer that records motion and speed of the subject. 
The Quality of Life Index (QLI) was used to measure life satisfaction related 
to the domains of family, health and functioning, social and economic, and 
psychological or spirituality. The majority of the patients were found to experience 
mild fatigue at baseline, which escalated following HSCT to significantly higher 
levels (p<0.001). Also after HSCT physical activity markedly decreased by 58% and 
overall health status became significantly worse. The significant decline in patients’ 
physical, emotional and cognitive functioning seemed to peak in the immediate post-
transplant period. The authors also found this decline in functioning and physical 
activity associated with significant increases in symptoms of fatigue, pain, nausea and 
vomiting, diarrhea, loss of appetite and sleep disturbance. The QLI scores of 
socioeconomic and psychological or spiritual subscales showed no significant 
changes in this study, allowing the authors to support the notion that a lag time exists 
between actual experiencing of health status changes and assimilating those changes 
into an appraisal of life’s circumstances (Hacker et al., 2006). The study findings 
suggest that patients experience prolonged fatigue and physical inactivity for at least 7 
to 14 days following HSCT. This prolonged inactivity may eventually lead to 
reduction of muscle mass and loss of strength and functional capacity. The 
consequences of this diminished functional capacity are of particular concern with 
patients’ ability to maintain or return to their productive roles in society (Hacker et al., 
2006). Therefore, maintaining levels of activity may enhance functional capacity and 
role performance towards improving patient’s perception of health status and QOL. 
This study further calls for effective management of fatigue symptoms experienced 
during the immediate period following stem cell transplant. 
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An earlier study by Harder et al. (2002) considered fatigue a main disease and 
treatment related predictor for cognitive impairment. Harder and colleagues examined 
the cognitive functioning and quality of life in long-term adult survivors of bone 
marrow transplant 22 to 82 months post treatment. The sample was comprised of 40 
disease-free patients treated with SCT for hematological malignancies, 87% of whom 
had undergone an allogeneic transplant. A battery of neuropsychological tests was 
used to assess the mental status and cognitive performance of the subjects. For QOL 
and mood states measurement the EORTC QLQ-C30 and the brief version of the 
Profile of Mood States (POMS) were utilized. POMS measures five dimensions of 
general psychological distress: depression, tension, anger, fatigue, and vigor. The 
authors found mild to moderate cognitive impairment in 60% of the subjects, 
especially in the areas of verbal learning, visual memory, selective attention and 
information processing speed. A substantial correlation was found between cognitive 
impairment and fatigue symptom on both EORTC QLQC30 (r= 0.55; p <0.001) and 
POMS scales (r=0.51, p< 0.001). A significant relationship was also found between 
fatigue, cognitive functioning and physical functioning. QOL and fatigue were 
significantly associated with depression measured by POMS.  
Fatigue remains a challenge for SCT patients even years after transplant. The 
findings of this study indicate that fatigue can predict late cognitive deficits in long 
term survivors. The authors reported that neuropsychological impairments and 
cognitive complaints were associated with increased absence from work and school. 
With such decreases in functional status, patients may experience role dissatisfaction 
and a reduction in quality of life. 
Clinicians mostly attribute fatigue to the nature of the cancer illness and the 
treatment regimens. However, it is not well understood why fatigue persists long after 
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treatment completion when the patients are disease free or in complete remission 
years after the transplant. Most recently in the Netherlands, Gielissen et al. (2007) 
explored this phenomenon of post SCT persistent fatigue in light of the precipitating 
and perpetuating theoretical model. The authors identified five perpetuating factors 
that influence the persistence of fatigue symptoms which include insufficient coping, 
fear of disease recurrence, cognitive dysfunction, sleep disturbance and dysregulation 
of activity. In a cross-sectional retrospective design, ninety-eight survivals of acute 
myeloid or lymphatic leukemia, chronic myeloid leukemia and non-Hodgkin’s 
lymphoma who received autologous and allogeneic SCT between 1981 and 2003, 
participated in the study. All patients had to be in persistent complete remission for at 
least one year after SCT, those with graft-versus-host disease (GVHD) grade III and 
IV or with hemoglobin of 10 g/dl and lower were excluded. This was done in order to 
make the sample less prone to fatigue than the general population of SCT. Several 
instruments were used to evaluate the prevalence of each of the perpetuating factors 
identified. Fatigue was measured using the fatigue severity subscale of the Checklist 
Individual Strength (CIS). A CIS fatigue score equal to or higher than 35 identified 
severe fatigue. Even long after receiving SCT (mean= 9.3 years) thirty-four patients 
(35%) met the criteria of severe fatigue and 12% had heightened fatigue scores. The 
data analysis revealed a very low non-significant correlation between fatigue scores 
and the length of hospital stay during transplantation. The correlation between CIS 
fatigue scores and time since transplantation, which ranged from 1 to 15 years, also 
proved to be low and non-significant. Patients with comorbidities such as 
hypertension, diabetes, infections and hepatitis C were found to have higher levels of 
fatigue (Gielissen et al., 2007). The authors also concluded that the perpetuating 
model explained and highly predicted the severity and the persistence of fatigue, 
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suggesting that several psychosocial factors, rather than medical factors, were mostly 
associated with persistent fatigue. 
Anderson et al. (2007) assessed symptom burden of patients during the acute 
phase of autologous transplant. The purpose of their study was to determine the 
severity of the symptoms experienced by patients and to identify predictors of high 
levels of symptom burden. The authors hypothesized that symptom intensity and 
related interference would increase post transplant and be most severe at nadir. The 
sample consisted of 100 patients with multiple myeloma or non-Hodgkin’s lymphoma 
undergoing autologous stem cell transplantation with matched conditioning regimens 
for each group. Assessment was carried out at baseline before commencing 
conditioning regimen, on the third to fourth day of the conditioning regimen, on the 
day of transplantation, on the day of nadir and on 30 days post-transplant. The 
subjects were asked to complete the blood and marrow transplantation module of the 
M. D. Anderson Symptom Inventory (MDASI-BMT), a measure of symptom severity 
and symptom related interference in daily life, and the Eastern Cooperative Oncology 
Group Performance Status (ECOG PS), which measures functional status, at each 
time point. Mood and quality of life were measured on baseline and on day 30 post-
transplant using the Profile of Mood States (POMS) and the Functional Assessment of 
Cancer Therapy–Bone Marrow Transplant (FACT-BMT) scales (Anderson et al., 
2007). The authors reported that over half of the patients complained of moderate to 
severe fatigue which interfered mostly with general activity, mood, walking, and 
enjoyment of life. The mean scores of symptom severity and symptom interference 
were significantly greater at nadir compared with baseline levels. Fatigue along with 
symptoms of weakness, feeling physically sick, disturbed sleep, nausea and vomiting 
showed the highest intensities. The severity of fatigue had a significant correlation 
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(p= 0.049) between the time point and the diagnosis. Patients with non-Hodgkin’s 
lymphoma reported higher levels of fatigue at baseline, on nadir, and on 30 day post-
transplant compared to the patients with multiple myeloma. Anderson et al. (2007) 
related this difference among these two groups to differences in the disease 
physiology or treatment history and conditioning regimens. Clinicians can help 
optimize symptom management, as they become aware of the different symptoms’ 
burden and pattern associated with the different diagnoses of SCT population 
(Anderson et al., 2007). 
Another research study addressing the symptom burden by Bevans, Mitchell 
and Marden (2008) was aimed at describing the symptom characteristics experienced 
in the post transplant period. Seventy-six adult patients with hematologic disorders 
undergoing their first matched related allogeneic SCT enrolled in this study. Data 
were utilized from a prospective study of health-related quality of life (HRQL) in 
which the participants were already enrolled. Symptom occurrence, distress, and 
clusters were measured using the Symptom Distress Scale (SDS). Based on the 11 
symptoms of nausea, appetite change, insomnia, pain, fatigue, bowel changes, 
concentration, appearance, worry (outlook), breathing, and cough; each symptom is 
rated on a 6-point Likert-type scale. Symptom distress was indicated as mild, 
moderate, or severe. To be considered clustered, symptoms had to at least be 
moderately and significantly related to one another and simultaneously independent of 
other SDS symptoms (Bevans et al., 2008). Medical Outcomes Short Form 36 Health 
Survey (SF-36 version 1) also was used to measure functional health and well being. 
Data were collected on baseline before conditioning commencement and on days 0, 
30, and 100 after allogeneic SCT. Bevans and colleagues reported that fatigue was 
among the most prevalent symptoms across study time points. Fatigue was reported 
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by 68% of participants at baseline, 86% of participants on day zero, 90% of 
participants on day 30 and 81% of participants at day 100 post-transplant. Fatigue 
occurrence was also prevalent in symptom clusters. At baseline, the most prevalent 
symptom cluster was fatigue and worry. On days 0 and 30 the symptom cluster 
consisted of fatigue, bowel change, and insomnia. Fatigue symptom distress was 
reported by six patients (11%) at day 100, but no symptom cluster was noted. The 
authors suggested that the extent of symptom distress, prevalence, and occurrence of 
fatigue in clusters emphasizes the importance of tailoring interventions to target 
fatigue according to the phase of recovery. Fatigue symptom distress predicts poor 
functional recovery, general health, and quality of life. Managing symptom distress 
may provide SCT population with an opportunity for better outcomes (Bevans et al., 
2008). 
Quality of Life 
In a prospective study by Hjermstad et al. (2004), health related quality of life 
(HRQOL), fatigue, anxiety, and depression were assessed in 248 patients with 
hematological or lymphocytic malignancies, following treatment SCT. The purpose of 
the study was to describe the fluctuations of those symptoms and HRQOL of the 
patients over a period of three years or more after completion of transplant, while 
comparing assessment scores between allogeneic SCT and autologous SCT groups 
with patients who received conventional chemotherapy (CT) alone. The EORTC 
QLQ-C30 questionnaire was utilized by the authors, is a 30-item tool which 
incorporates five functional scales (physical, role, emotional, cognitive, and social); a 
three symptom scales measuring fatigue, pain and nausea and vomiting; one scale 
assessing overall health/global QOL; and six single items to assess symptoms 
commonly reported by cancer patients such as dyspnea, sleep disturbances, appetite 
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loss, diarrhea, constipation and financial impact. The EORTC QLQ-C30 was 
administered nine times throughout the three-year study period. Measurement of 
physical and mental fatigue was assessed by the Fatigue Questionnaire (FQ). The FQ 
asks questions about fatigue symptoms experienced during the last month compared 
with how the subjects felt when they were well. Anxiety and depression symptom 
distress was measured using the Hospital Anxiety and Depression Scale (HADS).  
At baseline, a marked difference was found between allogeneic SCT and 
autologous SCT patients on the fatigue symptom scale and global QOL scores. The 
allogeneic SCT group experienced less fatigue and better quality of life at baseline, 
but greater impairment than autologous SCT patients on second week post transplant 
with an increase in fatigue symptoms and reduction in functional levels. Gradual 
improvement in symptomatolgy occurred at 4 to 8 months until levels returned to 
baseline at one year. In comparison, the autologous SCT group showed less 
fluctuation from the baseline scores and a more rapid recovery, as global QOL scores 
became similar to baseline or even better after four months only. The CT group 
showed a negative change in global quality of life after 4 to 6 months of treatment, 
where scores stabilized at a level significantly higher than baseline (Hjermstad et al. 
2004).  
The authors reported that despite that early recovery of the autologous SCT 
group they were found to report poorer functioning and more fatigue at three years 
after transplant. No statistically significant difference was reached for physical and 
mental FS scores, yet more autologous SCT patients reported chronic fatigue when 
compared to allogeneic SCT group, CT patients and the general population. There 
was no significant change in depression or anxiety scores across all groups. The 
authors also suggested that this pronounced impairment in QOL and the chronic 
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fatigue complaints of ASCT group, may be attributed to the extensive chemotherapy 
and radiation those patients received prior to transplant. These findings emphasize the 
importance of HRQOL assessment of stem cell transplantation recipients with focus 
on functional status and fatigue symptoms. It is also important to advise patients to 
maintain a close follow up with their health care providers to optimize the hospital to 
home environment transition (Hjermstad et al. 2004). 
 Schulmeister, Quiett, and Mayer (2005) explored the quality of life, quality of 
care, and patients’ satisfaction with outpatient autologous stem cell transplant (ASCT) 
experience. Forty adult patients undergoing ASCT were interviewed via telephone, 
three times, over a six-month period. To measure Quality of life, subjects were asked 
to complete the Functional Assessment of Cancer Therapy–BMT (FACT-BMT) scale 
during interviews at 4 to 6 weeks after chemotherapy and again at six months post 
chemotherapy. The FACT-BMT scale measures five dimensions of QOL including: 
physical, social/family, emotional, functional well-being, and BMT effects. 
Telephone interviews guided by open-ended questions were used to explore patients’ 
ASCT experiences and satisfaction with the outpatient ASCT process (Schulmeister et 
al., 2005). The authors found that patients who reported negative previous healthcare 
experiences had significantly lower scores on the emotional well-being subscale. 
Those who had progressive disease showed lower QOL and significantly more regret 
for having the transplant. Concentration and memory problems, which interfered with 
work, household responsibilities, leisure activities, and interpersonal relationships, 
were experienced by 22% of the patients. FACT-BMT scores were lowest one month 
post treatment and were highest six months post transplant. Higher QOL and greater 
satisfaction with care were associated with good clinical outcomes following ASCT. 
In general, the majority of the patients had reported a positive outpatient experience. 
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Although some of the patients reported that the outpatient ASCT experience did not 
feel personalized, they complained that the recommendations for self care and 
symptom management booklets, which they received in outpatient clinic, did not 
address their personal concerns and needs. Many complained that important treatment 
related issues such as: sexuality and fertility issues, complementary and alternative 
therapies, and long term side effects were underemphasized. Patients expressed a need 
for more information on how to maintain their strength and activity tolerance, fatigue, 
and skin problems management. They also expected post transplant psychosocial 
support to be offered for patients and families which could have further improved 
their quality of life (Schulmeister et al., 2005). 
 One of the strengths of this study was that it included both qualitative and 
quantitative research methods. The findings indicate the value of constructing 
individualized interviews with patients where clinicians can personalize the 
experience of SCT and address the most relevant concerns for each individual. The 
SCT experience is faced with much uncertainty and thus, as these authors suggested, 
the nurses should consider providing specific care plans including specific dietary 
suggestions and exercise prescriptions. Ongoing evaluation of the survivors’ needs 
and concerns would enhance patients’ satisfaction with the SCT experience and help 
optimize the associated quality of life.  
Summary 
 In summation, research has found that SCT related fatigue worsens in the 
acute post transplant period along with the quality of life (El-Banna et al., 2004; 
Hacker et al., 2006; Anderson et al., 2007). Many differing phenomena are associated 
with fatigue in post SCT individuals. These phenomena could be physiological with 
effects on strength, sleep pattern, and physical activity (Hjermstad et al., 2004), or 
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they could be cognitive, perceptual, motivational or psychological in nature (Harder et 
al., 2002). Higher levels of fatigue symptoms distress have been predictive of poor 
quality of life, poor general health, greater emotional distress, and overall mortality 
(Gielissen et al., 2007; Schulmeister et al., 2005).  
 Proper assessment of the fatigue dimensions is essential in combating this 
condition. Clinicians should be able to identify fatigue symptom distress in each 
phase of recovery (Bevans et al., 2008) and design appropriate individualized 
interventions with personalized patient education plans (Schulmeister et al., 2005). 
Most of the available literature on fatigue in stem cell transplant population focused 
on the acute recovery period. The current study is proposed to expand the knowledge 
base related to fatigue intensity, fatigue symptom distress, and their relationship with 
quality of life of long term adult survivors at least 5 months post stem cell 
transplantation.  
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Chapter III 
Methods 
This chapter presents the research methods and procedures that were used in 
this study. First the sample selection and setting are described. Second, methods of 
measurement including description of the Instruments with their validity and 
reliability are discussed. Third, research procedures are described including the data 
collection methods. Finally the data analysis plan is discussed. This descriptive, 
exploratory study used a cross sectional design to describe the relationship between 
fatigue symptom distress and quality of life (QOL) in stem cell transplant (SCT) 
survivors. 
Setting and Sample 
The research data were collected at Moffitt Cancer Center, a National Cancer 
Institute (NCI) designated comprehensive cancer center in southwest Florida. The 
target population for this study was adult SCT survivors who were at least six months 
following completion of SCT procedures including chemotherapy, total body 
irradiation therapy and stem cells transfusion. Inclusion criteria included: (1) being an 
adult over 18 years of age at the time of transplant, (2) incomplete or partial remission 
of underlying disease, (3) being able to read and understand English, and (4) 
willingness to participate in the study. Exclusion criteria for this sample included (1) 
active cancer treatment with chemotherapy, radiation, or immunotherapy in the past 6 
months, (2) hospitalization at the time of the study, (3) a history of chronic fatigue 
syndrome, fibromyalgia, or any comorbidity related fatigue history, and (4) a current 
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psychiatric diagnosis or neurological deficit that may impede the subject’s ability to 
comprehend the study. A sample of 50 adult BMT outpatients was sought.  
Instrumentation 
Three Instruments were used for this study, (1) The Cancer Related Fatigue 
Distress Scale (CRFDS), (2) The Functional Assessment of Cancer Therapy-Bone 
Marrow Transplant (FACT-BMT) version 4, and (3) a Demographic Data/Health 
Information Form. 
Cancer Related Fatigue Distress Scale 
The Cancer Related Fatigue Distress Scale (CRFDS) was used to collect data 
on fatigue symptom distress (Appendix A). The summated rating scale of 20 items 
addresses cognitive, physical, psychological, social and spiritual distress The CRFDS 
items have similar stem and response structure. Each item begins with: “The fatigue 
or tiredness I am having causes me distress because it...” followed by an item from 
distress categories (e.g., “Makes me too tired to eat “). The study participants were 
asked to rate their distress on an 11-point scale, ranging from 0 (no distress) to 10 
(severe distress). The CRFDS scores are based on how the subject has felt over the 
last week, therefore, lending itself to a more accurate reporting of one’s overall 
fatigue distress experience. The total possible scores of the scale ranges from zero to 
200, the higher the score, the greater the level of fatigue symptom distress. The 
CRFDS also includes three 0-10 fatigue intensity scales that measure "fatigue now" 
"usual fatigue in the past week," and "worst fatigue in the past week.” Zero represents 
no fatigue and ten as the most severe fatigue. The participants' performance status was 
measured using the Karnofsky Performance Status (KPS) Scale, to determine the 
participants' ability to perform daily activities (Holley, 2000).  
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Validity and Reliability. The CRFDS has strong content validity and high 
reliability. The items of this scale were constructed from 23 audio taped interviews 
with 17 patients who experienced cancer related fatigue (CRF). Patients’ input in 
developing the scale supported its construct validity. Factor analysis was used to 
assess construct validity which confirmed all items loaded on one factor, indicating 
that all items assessed CRF distress. Using a conservative standard of 0.70, 20 of the 
23 items met the standard and were retained. Factor loadings ranged from 0.589-
0.913. The measure also has shown significant pre to post score changes (p <0.001). 
Reliability for internal consistency estimate of this measure is very high, with 
coefficient alpha of 0.98 (Holley, 2000). 
Functional Assessment of Cancer Therapy–Bone Marrow Transplant 
 The Functional Assessment of Cancer Therapy–Bone Marrow Transplant 
(FACT–BMT) is a 39-item scale that measures five dimensions of QOL in BMT 
recipients including: physical (7 items), social/family (7 items), emotional (6 items), 
functional (7 items) well-being and a 12 item BMT-subscale. BMT specific items 
were designed to assess QOL content specific to the BMT process (Appendix B). 
Patients are asked to rate themselves on how they feel today and over the past 7 days. 
A 5-point Likert-type scale is used to rate each item of the questionnaire from 0 (not 
at all) to 4 (very much). Higher scores are associated with higher levels of satisfaction 
with QOL. The total scores for the FACT-BMT can range from 0–148. The FACT-
BMT was further expanded to include 23 items in the BMT subscale, resulting in 
FACT-BMT (Version 4) which more specifically measures the unique effects of BMT 
on QOL  Items that were added to the subscale included ability to concentrate, ability 
to remember things, experiencing blurry eyesight, experiencing frequent colds or 
infections, noting food taste changes, having tremors, experiencing shortness of 
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breath, having skin problems, experiencing bowel trouble, illness hardship on family 
members, and the cost of treatment (McQuellon et al., 1997). These items are 
considered experimental, with ongoing psychometric evaluation and currently are not 
included in the scoring. This data was not reported. Respondent’s burden of this 50-
items scale is considered minimal as the average time to completion is 5-10 minutes 
(McQuellon et al., 1997).  
Validity and Reliability. The FACT-BMT underwent a three-step validation 
process which involved testing of overall measures with subscales correlation and 
internal consistency calculations. Items of BMT subscale were selected from a list 
produced by seven oncology experts and 15 patients which enhances its construct 
validity. The BMT subscale demonstrated sensitivity to change over time at baseline, 
post-transplant, upon discharge and 100 days post transplant (McQuellon et al., 1997). 
Coefficients of reliability and validity for the entire scale are high. The authors found 
no significant difference between autologous or allogeneic SCT patients, or patients 
with Graft Versus Host Disease (GVHD) compared to those without GVHD. This 
supports more generalizability of this tool for the BMT population.  
Demographic Data/Health Information form  
Demographic and personal characteristics of the subjects were collected using 
the Demographic Data/Health Information Form (Appendix C). The data included in 
this form are: age, gender, ethnicity, educational background, marital status, and 
employment status. Questions were asked about underlying cancer diagnosis, type of 
transplant received and months from transplant completion, status of their cancer, and 
whether they received any cancer treatment in the past 6 months. These data were 
used to determine whether type of transplant and/or time from transplant influence the 
experience of persistent fatigue.
 
 
Procedures 
Approvals 
The principle investigator was responsible for assuring the research was 
implemented safely and effectively in accordance with the regulations of the 
Institutional Review Board (IRB) of the University of South Florida. Before obtaining 
the research approval of IRB, a behavioral research application was filed with the 
Scientific Review Committee of MCC. The benefit-risk ratio was assessed for this 
study, indicating the study design had minimal risk to subjects and important benefits. 
Informed consent (Appendix D) was designed to be easily understood and contained 
no coercive language. Upon approval of MCC (Appendix E) the proposal was 
submitted to IRB. Approval letter was obtained from IRB (Appendix F) along with 
approved consent stamped with IRB approval and expiration date.  
Data Collection 
A research flyer was used to advertise the study and was distributed around 
the BMT outpatient clinic, treatment center, and the clinic waiting areas at MCC. The 
Principle investigator’s (PI) phone number was provided in the flyer for interested 
individuals to contact and inquire about the study. The healthcare providers and 
support staff of BMT clinic also identified potential participants, initiated the contact, 
and referred them to the study. Upon visiting the outpatient clinic for scheduled BMT 
follow up appointments, patients met with the PI and the study was explained. If 
patients agreed to join the study, they completed a screening form which determined 
their eligibility to participate. 
The PI assessed potential participants using the inclusion/exclusion criteria. 
When sample criteria were met, written consent to participate was collected from 
patients and a copy of the signed informed consent was given to the participants to 
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keep. Patients participating in other MCC fatigue or quality of life studies were not 
asked to participate. Participants were taken to a private consult room, the study was 
explained to them, and they were instructed on how to complete the three 
questionnaires. Subjects were given the opportunity to ask questions about the 
research and the PI was available in the area for clarification. Forms were reviewed 
for completeness of response, staff and patients were thanked for their participation. 
Data were gathered from 33 subjects. The raw data collected and original consent 
forms were stored in a locked file drawer in the principle investigator’s locked office 
and will be kept for five years after completion of study and then shredded. 
Data Analysis 
 Descriptive statistics were performed for all variables. Tests were two-sided 
and a p value of 0.05 or less was considered statistically significant. All data were 
analyzed using the Statistical Package for Social Sciences (SPSS) for windows 
version 18 software. Demographic data were reported with frequencies, percentages, 
means, standard deviations, and ranges; which are presented in the sample 
characteristics table (Table 1). 
The research questions provided direction for this data analysis. For research 
question #1: What is the prevalence of fatigue and the level of fatigue symptom 
distress reported by cancer patients at least six months past completing SCT? The 
mean ratings of each item on the CRFDS were used to evaluate the levels of fatigue 
Intensity and fatigue distress described by the participants. 
Similarly, for research question #2: What do patients report their quality of life 
to be at least six months after SCT? Mean quality of life scores of FACT-BMT were 
calculated overall and among subscales. 
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For research question #3: Is there a significant relationship between fatigue 
symptom distress and quality of life of cancer patients at least six months after SCT? 
Pearson’s correlation coefficient (r) was utilized. 
Similarly, for research questions 4 and 5, the Pearson correlation was used to 
assess the association between time from transplant and fatigue symptom distress and 
quality of life.  
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Chapter IV 
Results, Discussion and Conclusion 
 The following chapter presents the findings of this study. First, the sample is 
described. Next, the research questions are addressed. The results, strengths and 
limitations of the study are discussed. The chapter also includes recommendations for 
nursing practice, nursing education, and nursing research. 
Results 
Sample  
 Thirty- nine (n = 39) BMT outpatients were approached to participate in the 
study. Four declined participation due to feeling tired, and thirty-five (n = 35) agreed 
to participate. Two of the completed questionnaires were discarded for incomplete 
information. Twenty-one males and 12 females participated in this study (N = 33) 
(Table 1). The mean age was 53 (SD = 9.79) with a range between 36 and 70 years. 
Of the 33 participants, 24 (73%) were married, 5 (15%) were single, 3 (9%) were 
divorced, and 1 (3%) was widowed. A majority of the patients were Caucasian (79%), 
followed by Hispanic (15%), and African American (6%). Seventy-six percent (n = 
25) of the recipients received allogeneic stem cell transplantation and the remainder 
underwent autologous SCT (n = 8). The mean length of time from transplant for 
surviving patients was 19.24 months (SD = 17.78; range = 6–84 months, n = 33). 
Among the participants the most frequently occurring diagnoses were non Hodgkin’s 
lymphoma (24%), followed by acute myeloid leukemia (21%), and acute lymphocytic 
leukemia (18%) (Table 2).
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Table 1 
Demographics and Clinical Characteristics of Patients 
 
Variable  Frequency Percentages 
Gender  
 Male 21 64 
Female 12 36 
Race/ethnicity 
 Caucasian  26 79 
Hispanic  5 15 
 African American  2 6 
Education 
0–11 2 6 
High school   10 30 
Some college   11 33 
College graduate   8 24 
Post graduate   2 6 
Marital status 
Married  24 73 
Single  5 15 
Separated/divorced  3 9 
Widowed  1 3 
Occupational status 
 Disability/unemployed  15 45.4 
Employed   13 39.4 
Retired  5 15.2 
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Table 2 
Diagnoses and Type of Transplant 
Variable   Frequency Percentages 
Diagnosis 
Non-Hodgkin lymphoma 8 24.2 
Acute myeloid leukemia 7 21.2 
Acute lymphocytic leukemia 6 18.2 
Multiple myeloma  5 15.2 
Myelodysplastic syndromes 3 9.2 
Chronic lymphocytic leukemia. 1 3 
Chronic myeloid fibrosis 1 3 
Chronic myeloid leukemia 1 3 
Small Cell Lung Carcinoma 1 3 
Type of transplant 
Allogeneic  25 76 
Autologous  8 24 
Fatigue Intensity and Symptom Distress 
 Research question 1: What is the prevalence and level of fatigue distress 
reported by cancer patients at least six months past completing SCT? Thirty-one 
participants (93.9%) reported persistent fatigue and five (15%) rated their fatigue 10 
out of 10 at its worst. The mean value of current fatigue reported by allogeneic 
transplant participants was 2.56 (SD= 2.33), and mean= 2.38 (SD= 1.69) for the 
autologous transplant subjects, for both groups combined the mean was 2.52 (SD= 
2.17). The mean usual fatigue of all participants was 2.85 (SD= 1.97), for allogeneic 
transplant participants the mean usual fatigue was 2.84 (SD= 2.07) and 2.88 (SD= 
1.73) for autologous transplant participants. The mean worst fatigue for all subjects 
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was 4.79 (SD= 3.07), 4.56 (SD= 3.09) for allogeneic transplant participants and 5.50 
(SD= 3.07) for autologous transplant participants (Table 3). The ratings of CRFDS 
were summed for each participant, the total scores ranged from 0–195, with a mean 
value of 61.8 (Table 4). 
Table 3 
Means, Standard Deviations and Ranges of Fatigue Intensity Scores 
Variable n Minimum Maximum Mean SD 
KPS scale 33   50  100  85  13.5 
 
 Total Fatigue intensity 
 Usual 33 0 7 2.85 1.97 
 Current 33 0 8 2.52 2.17 
Worst 33 0 10 4.79 3.07 
Allogeneic 
 Usual 25   2.84 2.07 
 Current 25   2.56 2.33 
 Worst 25   4.52 3.09 
Autologous  
 Usual 8   2.38 1.69 
 Current 8   2.88 1.73 
 Worst 8   5.50 3.07   
Note. n= number of subjects, SD= Standard Deviation. 
 Research question 2: What do patients report their quality of life to be at least 
six months after SCT? Total scores of the FACT-BMT ranged from a minimum of 57 
and a maximum of 145 with the mean of 113.78 (Table 4). 
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Table 4 
Means, Standard Deviations, and Ranges of Total Scores of CRFDS and FACT-BMT 
 n Minimum Maximum Mean SD 
CRFDS total 33 0 169 61.89 50.82 
FACT- 
BMT total 33 57 145 113.78 25.66 
 
 
Relationship between Fatigue Symptom Distress and QOL 
 Research question 3: Is there a significant relationship between fatigue 
symptom distress and quality of life of cancer patients at least six months after SCT? 
Pearson’s product-moment correlation coefficient (r) was used to calculate the 
relationship between the total scores of fatigue symptom distress levels from CRFDS 
and the total scores of QOL from FACT-BMT. A strong negative correlation (r= -.86, 
p <.0001) was found, which was statistically significant (Table 5). 
Relationship between Fatigue Symptom Distress and Time from Transplant  
 Research question 4: Is there a significant relationship between fatigue and 
time from transplant? To assess the association between time from transplant and 
fatigue symptom distress, Pearson’s product-moment correlation coefficient (r) was 
used. A moderate positive relationship was found between CRFDS total and the time 
from transplant (r= .46, p= .007). This finding was statistically significant (Table 5). 
Relationship between QOL and Time from Transplant 
 Research question 5: Is there a significant relationship between quality of life 
and time from transplant? The Pearson correlation coefficient was used to examine 
the relationship between QOL and time from transplant. A moderate negative 
correlation was found (r= -.34, p=.052) which did not reach statistical significance 
(Table 5). 
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Table 5 
 
Pearson Correlation Coefficients between Fatigue Symptom Distress, Quality of Life, and 
Time from Transplant 
 
  Fatigue Symptom Distress  Quality of Life 
Variable 
  n r p n r p 
 
Quality of life 33 -.86 <.0001  33 1 ___ 
Time from Transplant 33 .46 .007  33 -.34 .052 
 
Discussion 
Sample 
 In this study, a convenience sample of 33 men and women was accrued at the 
comprehensive cancer center MCC. When the participants came to the BMT clinic 
for post transplant follow up visits they met with the PI and completed the consent 
form meeting all institutional, state, and federal guidelines. They also completed the 
CRFDS and FACT-BMT with an attached demographic data form. The tools took 
approximately 20 minutes to complete. A minimal respondents’ burden is of a 
particular importance when measuring fatigue in individuals who may already have 
attentional deficits, lack of energy, and feelings of tiredness. 
  A limitation of the sample is that it did not represent the SCT types accurately 
for the BMT population. The majority of the participants underwent allogeneic stem 
cell transplant, and only eight of them had autologous SCT. In addition, although 
participation criteria were nonexclusive of ethnicity groups or racial backgrounds, 
minorities were not well represented in this sample. There were also more men than 
women participants. Strength of the sample is the diversity of the underlying 
diagnosis which included eight different types of cancer, which is a good 
representation of the SCT population. 
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Fatigue, Symptom Distress, and Quality of Life 
 This study identified that fatigue is widely prevalent among BMT long term 
survivors; approximately 93% of the subjects experience some degree of fatigue 
according to the fatigue intensity scale of CRFDS. The literature reviewed in this 
study supports this finding. Gielissen et al. (2007) reported that side effects of BMT 
often precipitate heightened levels of fatigue. In this study, 5 participants (15%) rated 
their fatigue 10 out of 10 at its worst. This finding is in agreement with the 
assumption that patients with more aggressive treatments such as BMT are more at 
risk for persistent fatigue. The CRFDS total scores ranged from 0–195, with a mean 
of 61.8. The mean of fatigue symptom distress is considered somewhat low. A 
possible explanation for the inconsistency between the literature reviewed and this 
study finding is the diversity of underlying diagnoses and the difference in the type of 
BMT. Also, it should be considered that CRFDS measures the distress and suffering 
that accompanies the experience of fatigue symptom. Although fatigue symptom was 
quite prevalent among the participants, fatigue intensity can occur in variable levels 
that are not necessarily altogether distressful. 
 In this study, the majority of patients (76%) received allogeneic SCT. Those 
who received autologous transplant (24%) reported less fatigue symptom distress 
with mean= 48.0 (SD= 36.62), compared to the allogeneic transplant group (mean= 
66.2, SD= 54.49). Although this difference did not reach statistical significance (p= 
0.71) it is considered clinically significant. A possible explanation of this difference is 
that autologous SCT patients underwent a shorter hospital stay during transplant, had 
fewer complications and had no risk for GVHD compared to allogeneic transplant 
patients. In this sample of patients it was also found that fatigue symptom distress in 
allogeneic transplant subjects have been more severe. Harder et al. (2007) also related 
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that to their exposure to acute and chronic GVHD and other complications related to 
immunosuppression or immunosuppressive therapy. However, this finding should not 
distract from the fact that some autologous transplant participants did report fatigue 
symptom distress which should still be addressed on individual bases.  
 The total FACT-BMT scores ranged from 57-145. The mean score was 
113.78. This study found moderate levels of QOL. Schulmeister, Quiett and Mayer 
(2005) reported that higher QOL and greater satisfaction were associated with good 
clinical outcomes following transplant though there were lingering fatigue effects. 
Gielissen et al. (2007) also reported that fatigue persists long after treatment had 
ended. 
Relationship between Fatigue Symptom Distress and QOL 
 A strong significant negative correlation (r= -.85, p <.0001) was found 
between reported levels of fatigue symptom distress and QOL in this sample. The 
greater the levels of fatigue symptom distress, the poorer the quality of life. This 
negative correlation was an expected finding, and it supports the idea that persistent 
fatigue has a detrimental consequence on QOL of BMT long term survivors. 
However, a correlational study does not confirm cause and effect. This study supports 
the findings of Hjermstad et al. (2004) who reported an inverse relationship between 
fatigue, cognitive or social function and QOL. 
Relationship between Time from Transplant, Fatigue Symptom Distress and QOL 
 A significant moderate positive correlation was found between CRFDS total 
scores and the time from transplant (r= .46, p= .007). This correlation may be 
precipitated by emotional rather than physical distress; that is, those who had the 
longest survival seemed more distressed by fatigue. This relationship may occur 
because they expected a resolution of their symptoms and a sooner return to 
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normalcy. For patients closer to the time of transplant, there is reason to be hopeful 
that fatigue symptoms will fade away when they return to their normal functional 
levels and regain their full strength.  
A moderate negative relationship was found between QOL and time from 
transplant, supporting the idea that lingering fatigue does affect the quality of life. 
Although a shorter time from transplant correlated with higher QOL levels (r= -.34, 
p=.052) this finding did not reach statistical significance. It should also be noted that 
the most well-functioning transplant patients completed the questionnaires, while the 
most ill, most fatigued patients declined participation. Approximately 10% of these 
patients stated upon request that they did not feel well, they felt tired, and that was 
why they did not want to take part in the study. The failure of these patients to 
participate might have biased the study results in some important ways. 
Conclusions 
Implications for Nursing 
 This study supports the importance of addressing fatigue symptoms in patients 
who have undergone BMT as a possible approach to improving overall QOL. The 
study findings reflect that approximately 93% of the participants in this study 
experience some degree of fatigue after transplant. Also, it demonstrated a significant 
negative relationship between fatigue symptom distress and quality of life. This is 
relevant to nursing care and patient education. It would be highly advisable to inform 
the patients prior to transplant of the potential of developing some persistent fatigue 
that they may find to be distressing. The consequences of this can be diminished 
functional capacity which is of particular concern with patients’ ability to maintain or 
return to their productive roles in society (Hacker et al. 2006). Therefore, it is equally 
important to maintain levels of activity to enhance functional capacity and role 
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performance towards improving patient’s perception of health status and QOL. 
Understanding the relationship between fatigue symptom distress and QOL should 
encourage interdisciplinary collaboration in planning proper interventions to minimize 
fatigue. This would improve the outcomes of BMT long term survivors and would 
positively impact their overall quality of life. 
Implications for Research 
 A limitation of this study is that the patients with the worst BMT experience 
probably were not accessible because of their fatigue. Future studies with larger 
sample size should evaluate the specific chemotherapeutic agents or dosages used in 
BMT conditioning protocols and determine whether they impact the occurrence, 
frequency and persistence of fatigue. Similarly, the cross sectional design of this 
study lacks pre-treatment baseline assessment which precludes definite conclusions 
about a change in fatigue and QOL over time. A longitudinal cohort study using a 
comprehensive psychosocial test to investigate the effects of BMT treatment on the 
QOL of adult long term survivors is warranted.  
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Appendix A: Cancer Related Fatigue Distress Scale (CRFDS) 
CANCER RELATED FATIGUE DISTRESS SCALE  
(CRFDS) 
Sandra Holley, PhD, ARNP 
Instruction:   
Below and on the next 3 pages is a list of problems people sometimes have because of 
their cancer related fatigue. Please read each one carefully. Please circle the number 
that best describes HOW MUCH THAT PROBLEM HAS DISTRESSED OR 
BOTHERED YOU DURING THE PAST 7 DAYS, INCLUDING TODAY. Circle 
only one number for each problem and do not skip any items. If you change your 
mind, erase your first mark carefully. Read the example before beginning, and if you 
have any questions please ask them now. 
 
Please complete all 20 items and the 3 additional items on the last page. 
 
The fatigue or tiredness I am having causes me distress because it: 
 
1. Makes it difficult for me to concentrate. 
 
How much distress does this cause you? 
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
2. Makes me feel that I must accept more help from others. 
 
How much distress does this cause you? 
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
3. Makes me feel that I am more than just tired. 
 
How much distress does this cause you? 
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
4. Makes me feel frustrated when I can’t do what I used to do. 
 
How much distress does this cause you? 
 
0 1 2 3 4 5 6 7 8 9 10 
No distress                                                                                                          Severe distress 
 
5. Makes my body feel as though it doesn’t want to function. 
How much distress does this cause you? 
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
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Appendix A (Continued) 
 
The fatigue or tiredness I am having causes me distress because it: 
 
6.  Makes it difficult for me to form whole thoughts. 
 
How much distress does this cause you?  
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
7.  Makes me feel like my physical abilities are being worn away. 
 
How much distress does this cause you? 
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
8.  Makes me feel that I am still tired after sleeping. 
 
How much distress does this cause you?  
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
9.  Makes me feel guilty when I can’t do the things that are my usual jobs to do. 
 
How much distress does this cause you?  
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
10.  Makes me too tired to eat. 
 
How much distress does this cause you? 
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
11. Makes me limit my family and social activities. 
 
How much distress does this cause you? 
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
12.  Makes me feel tired more quickly than typical fatigue. 
 
How much distress does this cause you?  
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
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Appendix A (Continued) 
 
The fatigue or tiredness I am having causes me distress because it: 
 
13.  makes me feel uncertain about my future. 
 
How much distress does this cause you?  
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
14.  Makes me feel totally exhausted. 
 
How much distress does this cause you? 
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
15.  Makes me feel like I am a different person. 
 
How much distress does this cause you? 
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
16.  Makes me stay at home more. 
 
How much distress does this cause you?  
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
17.  Makes me feel a loss of control over my life. 
 
How much distress does this cause you? 
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
18.  Makes it difficult for me to remember things. 
 
How much distress does this cause you?  
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
19.  Makes me feel as if I have no energy. 
 
How much distress does this cause you?  
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
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Appendix A (Continued) 
 
The fatigue or tiredness I am having causes me distress because it: 
 
 
20.  Makes me feel like I am losing interest in things. 
 
How much distress does this cause you?  
 
0 1 2 3 4 5 6 7 8 9 10 
No distress Severe distress 
 
 
Please circle the number that most describes your fatigue. 
 
     No fatigue        Severe fatigue 
Fatigue level now  0 1 2 3 4 5 6 7 8 9 10 
 
Worst fatigue level 
this past 7 days   0 1 2 3 4 5 6 7 8 9 10 
 
Usual fatigue level 
for the past 7 days  0 1 2 3 4 5 6 7 8 9 10 
 
 
Please circle the one number below that best describes your situation now 
 
KARNOFSKY PERFORMANCE SCALE 
 
 
 
100    Normal; no complaints; no evidence of disease 
     90   Able to carry on normal activity; minor signs of symptoms of disease 
80   Normal activity with effort; some sign or symptoms of disease 
70   Cares for self; unable to carry on normal activity or do active work 
60   Requires occasional assistance, but is able to care for most personal needs 
50   Requires considerable assistance and frequent medical care 
40   Disabled; requires special care and assistance 
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Appendix B: Functional Assessment of Cancer Therapy–Bone Marrow Transplant 
(FACT-BMT) 
 
Below is a list of statements that other people with your illness have said are 
important. Please circle or mark one number per line to indicate your 
response as it applies to the past 7 days. 
 
PHYSICAL WELL-BEING 
 
Not 
at all 
A 
little 
bit 
Some
what 
Quite 
a bit 
Very 
much 
I have a lack of energy 0 1 2 3 4 
I have nausea 0 1 2 3 4 
Because of my physical condition, I have 
trouble meeting the needs of my family 
 
0 
 
1 
 
2 
 
3 
 
4 
I have pain 0 1 2 3 4 
I am bothered by side effects of treatment 0 1 2 3 4 
I feel ill 0 1 2 3 4 
I am forced to spend time in bed 0 1 2 3 4 
 
SOCIAL/FAMILY WELL-
BEING 
 
Not 
at all 
A 
little 
bit 
some
what 
Quite 
a bit 
Very 
much 
I feel close to my friends 0 1 2 3 4 
I get emotional support from my family 0 1 2 3 4 
I get support from my friends 0 1 2 3 4 
My family has accepted my illness 0 1 2 3 4 
I am satisfied with family communication 
about my illness 
 
0 
 
1 
 
2 
 
3 
 
4 
I feel close to my partner (or the person who 
is my main support) 
 
0 
 
1 
 
2 
 
3 
 
4 
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 Regardless of your current level of sexual activity, please answer the following 
question. If you prefer not to answer it, please mark this box              and go to the next 
section. 
I am satisfied with my sex life 0 1 2 3 4 
 
 
 
Appendix B (Continued) 
 
Please circle or mark one number per line to indicate your response as it 
applies to the past 7 days. 
 
 
EMOTIONAL WELL-BEING Not 
at all 
A 
little 
bit 
Some
-what 
Quite 
a bit 
Very 
much 
I feel sad 0 1 2 3   4 
I am satisfied with how I am coping with my 
illness 
0 1 2 3 4 
I am losing hope in the fight against my 
illness 
0 1 2 3 4 
I feel nervous 0 1 2 3 4 
I worry about dying 0 1 2 3 4 
I worry that my condition will get worse 0 1 2 3 4 
 
 
 
FUNCTIONAL WELL-BEING 
 
Not 
at all 
A 
little 
bit 
Some
-what 
Quite 
a bit 
Very 
much 
I am able to work (include work at home) 0 1 2 3 4 
My work (include work at home) is fulfilling 0 1 2 3 4 
I am able to enjoy life 0 1 2 3 4 
I have accepted my illness 0 1 2 3 4 
I am sleeping well 0 1 2 3 4 
I am enjoying the things I usually do for fun 0 1 2 3 4 
I am content with the quality of my life right 0 1 2 3 4 
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Appendix B (Continued) 
Please circle or mark one number per line to indicate your response as it 
applies to the past 7 days. 
 
ADDITIONAL CONCERNS 
 
Not 
at all 
A 
little 
bit 
Some 
what 
Quite 
a bit 
Very 
much 
I am concerned about keeping my job (include 
work at home) 
 
0 
 
1 
 
2 
 
3 
 
4 
I feel distant from other people 0 1 2 3 4 
I worry that the transplant will not work 0 1 2 3 4 
The effects of treatment are worse than I had 
imagined 
0 1 2 3 4 
I have a good appetite 0 1 2 3 4 
I like the appearance of my body 0 1 2 3 4 
I am able to get around by myself 0 1 2 3 4 
I get tired easily 0 1 2 3 4 
I am interested in sex 0 1 2 3 4 
I have concerns about my ability to have 
children 
0 1 2 3 4 
I have confidence in my nurse(s) 0 1 2 3 4 
I regret having the bone marrow transplant 0 1 2 3 4 
I can remember things 0 1 2 3 4 
I am able to concentrate 0 1 2 3 4 
I have frequent colds/infections 0 1 2 3 4 
My eyesight is blurry 0 1 2 3 4 
I am bothered by a change in the way food 
t t
0 1 2 3 4 
I have tremors 0 1 2 3 4 
I have been short of breath 0 1 2 3 4 
I am bothered by skin problems (rash, itching) 0 1 2 3 4 
I have trouble with my bowels 0 1 2 3 4 
My illness is a personal hardship for my close 
family members 
 
0
 
1
 
2 
 
3 
 
4
The cost of my treatment is a burden on me or 
my family 
 
0 
 
1 
 
2 
 
3 
 
4 
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Appendix C: Demographic Data/Health History Information Form 
 
Part A: Demographic data 
1. Age___ (Please, do NOT provide your date of birth) 
2. Gender: Male ____ Female ____ 
3. Ethnicity/Race (check one) 
___ American Indian/Alaska Native              ___ Arab American 
___ Asian American/Pacific Islander             ___ Black/African American  
___ Caucasian/White/Anglo   ___ Hispanic/Latino  
___ Other 
4. Educational background___________________ (Highest grade completed) 
5. Marital status: Single ___ Married ___ Widowed ___ Separated ___ Divorced___ 
6. Employment status: 
___ Self employed ___ Employed outside the house 
___ Disability ___no ___ yes, specify: ________________________________ 
 
Part B: Health History Information 
Underlying Cancer diagnosis: _______________________________________ 
Type of Transplant received: (Check one)  
___ Bone Marrow Transplant ___ Blood/Stem Cell Transplant ___ Cord Blood 
___ Allogeneic Transplant (from a donor) ___ Autologous Transplant (from self) 
Number of months from Transplant completion ______ 
Are you in complete or partial remission? Complete ___ Partial___ I don’t know__ 
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 Appendix D: Informed Consent 
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Appendix D (Continued)  
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Appendix D (Continued) 
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Appendix D (Continued) 
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Appendix E: Moffitt Cancer Center Scientific Review Committee approval 
 
 
 
 
August 14, 2009 
 
  
Suzan Abduljawad  
H. Lee Moffitt Cancer Center & Research Institute  
University of South Florida  
12902 Magnolia Drive  
Tampa, FL 33612 
 
Dear Ms. Abduljawad:  
 
The Behavioral Subcommittee of the Scientific Review Committee (SRC) has 
reviewed your response for your research protocol entitled, “Fatigue Symptom 
Distress and Its Relationship with Quality of Life in Adult Stem Cell 
Transplant Survivors” (MCC 16029). The revised protocol version dated 
08/11/2009 is approved as written for use at the Moffitt Cancer Center pending 
approval of the Institutional Review Board (IRB) and satisfaction of institutional 
operational and financial review requirements. Please be aware that after you 
receive IRB approval, you must request study activation before you commence 
any study activities. The Protocol Review and Monitoring System will ensure that 
all applicable institutional reviews have been completed. You will then be issued 
an activation letter. Upon receipt of the activation letter, you will be able to 
conduct your study.  
 
It is your responsibility to ensure that all Moffitt staff (nursing, pharmacy, data 
management, etc.) is informed and aware of the details of the project. The 
committee encourages the use of in-services for those projects that are complex 
or require special attention.  
 
All changes made to protocols approved by the SRC must be submitted to the 
Protocol Review and Monitoring System. Changes made to the protocol 
document require SRC review and approval. Minor changes (i.e. changes to 
personnel, non-scientific changes, changes that do not affect patient 
participation) will be expedited through the SRC review process.  
 
If this project is not being managed by the Clinical Trials Office or Clinical 
Research Unit, then it is your responsibility to follow through with all requirements 
for submission to the IRB. All IRB approvals are required to be documented in 
Oncore, and all associated regulatory documentation (signed applications, IRB 
approval letters and IRB approved consent forms, etc.) are to be saved in the 
appropriate study folder in the e-binders directory at J:\ebinders. 
 
Oncore is the Cancer Center’s mechanism for required submission and review of 
materials requiring IRB review as well as items requiring review by the Scientific  
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Appendix E (Continued) 
 
Review and Protocol Monitoring Committees. If you are not currently reporting 
the necessary research activities, such as patient accrual, changes in procedure, 
adverse events and continuing reviews in Oncore, please contact Jeryl Madden, 
Oncore Coordinator, at 745-6964 for direction. 
 
Sincerely,  
 
 
 
 
Paul Jacobsen, PhD  
Chair, Behavioral Subcommittee  
Scientific Review Committee 
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Appendix F: Institutional Review Board Approval 
 
DIVISION OF RESEARCH INTEGRITY AND COMPLIANCE 
Institutional Review Boards, FWA No. 00001669   
12901 Bruce B. Downs Blvd., MDC035.Tampa, FL 33612-4799 
(813) 974-5638FAX (813) 974-5618 
 
September 3, 2009  
 
Suzan Abduljawad 
College of Nursing  
Tampa FL 33612  
 
RE: Expedited Approval for Initial Review 
IRB#: 108313 I 
Title: Fatigue Symptom Distress and its Effect on Quality of Life in Adult Stem Cell  
Transplant Survivors 
Study Approval Period: 08/31/2009 to 08/30/2010  
 
Dear Ms. Abduljawad:  
 
On August 31, 2009, Institutional Review Board (IRB) reviewed and APPROVED the above 
protocol for the period indicated above. It was the determination of the IRB that your study 
qualified for expedited review based on the federal expedited category number five (5) and 
seven (7).  
 
Approval included with the Moffitt Adult Informed Consent Form. 
 
Please note, if applicable, only use the IRB-Approved and stamped consent forms for 
participants to sign. The enclosed informed consent/assent documents are valid during the 
period indicated by the official, IRB-Approval stamp located on page one of the form. Make 
copies from the enclosed original. 
 
Please reference the above IRB protocol number in all correspondence regarding this 
protocol with the IRB or the Division of Research Integrity and Compliance. In addition, you 
can find the Institutional Review Board (IRB) Quick Reference Guide providing guidelines 
and resources to assist you in meeting your responsibilities in the conduction of human 
participant research on our website. Please read this guide carefully. It is your responsibility 
to conduct this study in accordance with IRB policies and procedures and as approved by the 
IRB. 
 
We appreciate your dedication to the ethical conduct of human subject research at the 
University of South Florida and your continued commitment to human research protections. If 
you have any questions regarding this matter, please call 813-974-2036 
 
Sincerely, 
 
Krista Kutash, Ph.D., Chairperson 
USF Institutional Review Board 
 
Cc: Various Menzel/cd, USF IRB Professional Staff 
    Susan McMillan PhD 
